809 TOBACCO CESSATION CLINIC AND WHO'S MPOWER POLICIES

2011 ◽  
Vol 12 (1) ◽  
pp. 170
Author(s):  
A. Aggarwal ◽  
S. Dwivedi ◽  
P. Jain
2020 ◽  
Vol 31 (6) ◽  
pp. 852
Author(s):  
Abhishek Mehta ◽  
Sofiya Ahmed ◽  
Aditi Verma ◽  
Ratika Kumar

2019 ◽  
Vol 5 (Supplement) ◽  
Author(s):  
Qamar Goraya

Author(s):  
Rafat Hussam Abushanab ◽  
Abdullah H. Alshehri ◽  
Abdullah Muidh Y. Alqthami ◽  
Abdulsalam Alshehri

Smoking is a global health risk factor despite the efforts to control and the existance of tobacco cessation program. The objective of this study was to measure the proportion of people who failed to quit smoking at the end of six months after attending the smoking cessation clinic and to identify the factors associated with failure to quit. We used an analytical cross-sectional design which was conducted at Taif city, Saudi Arabia between January 2019 and March 2020. The attendees of smoking cessation clinic were invited to participate in the study. We used a questionnaire as the data collection too. The statistical package for the social sciences (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp ) was used to analyze the data. The total responses was 393, out of them  201 (51.1%) failed to quit smoking after six months. Age, marital status, income, and occupation were significantly associated with the outcome variable (quit or not). Even before attending the clinic (62.3%) have indicated previous failed attempts. Among the different types of smoking, hookah showed a significant association with failure, while nicotine dependence did not showed any significance. Failure to quit was associated with advanced age, smoking hookah, while those who indicated the price of tobacco products as a reason to quit were more prone to fail in quitting smoking. In conclusion, smoking cessation can be influenced by a sociodemographic factors, willingness and family support. Smoking hookah is associated with higher rates of failure to quit smoking.


Lung India ◽  
2012 ◽  
Vol 29 (2) ◽  
pp. 137 ◽  
Author(s):  
PremK Mony ◽  
George D′Souza ◽  
Priya Sreedaran ◽  
DorothyP Rekha ◽  
K Srinivasan

2011 ◽  
Vol 6 (1) ◽  
pp. 65-73 ◽  
Author(s):  
Dane Shiltz ◽  
Angie Paniagua ◽  
James E. Hastings

AbstractPurpose:To determine whether the combination of bupropion SR and varenicline offers improved smoking cessation outcomes compared to varenicline monotherapy or to combination of bupro-pion SR and nicotine patch.Methods:This retrospective chart review included 489 volunteer enrolees in a Veterans Affairs (VA) tobacco cessation clinic who received one of the three treatments upon clinic enrolment. The study endpoints were smoking cessation and clinic completion rates, changes in the number of cigarettes smoked, carbon monoxide (CO) levels, urges to smoke, self-confidence to quit and medication-attributed adverse effects.Results:The relative smoking cessation rates were 33%, 32%, and 40% for bupropion SR and nicotine patch, bupropion SR and varenicline, and varenicline groups, respectively. The 0.21 p value established that no significant cessation rate differences existed between any of the groups. Varenicline alone or in combination was as well tolerated as the combination of bupropion SR and nicotine patch.Conclusions:The combination of bupropion SR and varenicline did not demonstrate any smoking cessation advantage over varenicline monotherapy or the combination of bupropion SR and nicotine patch and therefore do not support the use of bupro-pion SR and varenicline over varenicline monotherapy.


2009 ◽  
Vol 66 (18) ◽  
pp. 1610-1614 ◽  
Author(s):  
Jessica E. Harris ◽  
Timothy C. Chen ◽  
Seung-Bin Kim ◽  
Khanh L. Nguyen

Sign in / Sign up

Export Citation Format

Share Document